Marine Compounds and Cancer 2020
Material type:
ArticleLanguage: English Publication details: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021Description: 1 electronic resource (480 p.)ISBN: - books978-3-0365-0631-9
- 9783036506302
- 9783036506319
- Medicine
- apoptosis
- fucoidan
- hepatocellular carcinoma
- reactive oxygen species
- 3-alkylpyridinium polymers
- nicotine
- nicotinic acetylcholine receptor
- non-small cell lung carcinoma
- melanoma
- sinulariolide
- proteomic
- mitochondria
- caspase cascade
- marine fungus
- sediment
- anthranilic acid
- Penicillium paneum
- cytotoxicity
- dibromotyrosine
- mitochondrial dysfunction
- oxidative stress
- topoisomerase
- epigonal organ
- bonnethead shark
- Jurkat
- tumor cell line
- hippuristanol
- PEL
- AP-1
- STAT3
- Akt
- colorectal cancer
- marine mollusc
- brominated indoles
- shrimp
- chemoprevention
- fatty acids
- carotenoids
- cancer
- nanoparticle
- osteosarcoma
- lung metastasis
- elisidepsin
- lipid rafts
- hydroxylated lipids
- fatty acid 2-hydroxylase
- cooperative binding
- membrane permeabilization
- marine organisms
- polysaccharides
- anticancer
- anticarcinogenic
- mechanisms of action
- fumigaclavine C
- anti-proliferation
- mitochondrial pathway
- anti-cancer
- anti-proliferative
- carotenoid
- cell cycle arrest
- fucoxanthin
- azoxymethane
- bioactive natural product
- isatin
- in vivo model
- Marthasterias glacialis L
- palmitic acid
- ER-stress
- CHOP
- Antibody Drug Conjugates (ADCs)
- marine antitumor agents
- clinical trials
- approved antitumor agents
- AD0157
- angiogenesis
- marine drug
- pyrrolidinedione
- secondary metabolites
- cancer preventive
- chemopreventive
- trabectedin
- plitidepsin
- tumor-associated macrophages
- tumor microenvironment
- preclinical
- anticancer immunity
- antiangiogenesis
- fascaplysin
- cyclin-dependent kinase
- small cell lung cancer
- camptothecin
- poly(ADP-ribose)-polymerase inhibitor
- breast cancer
- seaweed
- therapeutic compounds
- autophagy
- marine drugs
- autophagy inhibitors
- autophagy inducers
- macrolide
- programmed cell death
- energy stress
- araguspongine C
- c-Met
- HER2
- gemcitabine
- pazopanib
- phase I
- safety
- soft tissue sarcoma
- pachastrissamine
- jaspine B
- carbocyclic analogue
- sphingosine kinase inhibitor
- molecular modeling
- ET-743
- DNA minor groove binder
- soft tissue sarcoma
- chemotherapy
- bis (2,3-dibromo-4,5-dihydroxy-phenyl)-methane (BDDPM)
- anti-metastatic activity
- cell adhesion
- β1-integrin
- FAK
- BEL-7402 cell
- triterpene glycosides
- sea cucumbers
- antitumor activities
- arrest of cell cycle
- antibacterial
- marangucyclines
- deep-sea
- Streptomyces sp. SCSIO 11594
- LS-1
- SNU-C5/5-FU
- TGF-β signaling
- carcinoembryonic antigen
- kalkitoxin
- Moorea producens
- mitochondria toxin
- VEGF
- angiogenesis inhibitor
- hypoxia-inducible factor-1
- HIF-1
- Lyngbya majuscula
- marine metabolites
- SZ-685C
- nonfunctioning pituitary adenomas
- Ecklonia cava
- phlorotannins
- dieckol
- migration
- sipholenol A
- ABC transporter
- multidrug resistance
- P-gp/ABCB1
- BCRP/ABCG2
- MRP1/ABCC1
- marine natural products
- glioblastoma
- xyloketal B
- proliferation
- TRPM7
- marine compound
- ribosomal protein genes
- snoRNA
- FAU
- RPS30
- SNORA62
- evolution
- Porifera
- n/a
- Penicillium brevicompactum
- Brevianamide
- Mycochromenic acid derivative
- antifouling
- Caribbean sponge
- plakortide
- endoperoxide
- leukemia
- multi-drug resistant leukemia
- Sarcophyton ehrenbergi
- soft coral
- terpenes
- cembranoids
- cytotoxic activity
- molecular docking
- uveal melanoma
- oxidative stress
- virtual screening
- Topo I inhibitor
- low toxic
- natural product
- Ulva fasciata
- selenium-containing polysaccharide-protein complex
- pseudopterosin
- NF-κB
- p65
- inflammation
- cytokine release
- IL-6
- TNFα
- MCP-1
- glucocorticoid receptor
- paulomycins
- Micromonospora
- antitumor
- Cantabrian Sea-derived actinobacteria
- puupehenones
- sponges
- antiangiogenic
- antitumoral
- porifera/sponge
- cancer genes
- molecular oncology
- bromophenol
- molecular mechanisms
- cell cycle
- PI3K/Akt
- p38/ERK
- ROS
- human lung cancer
- glycosaminoglycans
- antiproliferative
- heparan sulphate
- gliotoxin
- NSCLC
- adriamycin resistance
- Sepia ink polysaccharides
- antitumour
- chemosensitization
- anticoagulation
- sea anemone
- drug discovery
- endothelial cells
- RGD motif
- kunitz type inhibitor
- prostate cancer
- antioxidant
- natural marine compounds
- marine biotechnology
- microalgae
- marine sponges
- Aeroplysinin
- Isofistularin
- pheochromocytoma and paraganglioma
- metastasis
- cancer progression
- cell adhesion molecules
- integrin β1
- hypoxia
- phycocyanin
- non-small cell lung cancer
- NF-κB signaling
- marine-derived drugs
- bioanalysis
- chromatography
- manzamine A
- epithelial-mesenchymal transition
- lung cancer
- circulating tumor cells
- signal transduction
- cisplatin
- Lampetra morii
- buccal gland
- cystatin F
- anti-angiogenesis
- cystatin superfamily
- Antimicrobial peptide (AMP)
- Tilapia piscidin 4 (TP4)
- non-small cell lung cancer (NSCLC)
- itampolin A
- FBDD
- p38α
- novel inhibitor
- tetracenomycin X
- cyclin D1
- proteasomal degradation
- p38
- c-JUN
- λ-carrageenan
- heparanase
- anticoagulant
- depolymerisation
- cell migration
- Aspergillus
- naphthopyrones
- endophytic fungus
- Leathesia nana
- mangrove-derived actinomycete
- ansamycins
- divergolides
- apoptosis-inducing activity
- actinomycin
- EMT
- invasion
- low molecular weight fucoidan extract
- N-Ras
- neuroblastoma-rat sarcoma
- Cancer
- programmed cell death-ligand 1
- programmed cell death-ligand 2
- human sarcoma cell line (HT1080 cells)
- human normal diploid fibroblast (TIG-1 cells)
- chimera
- chemical conjugation
- anticancer agent
- hybridization
- α9-nicotinic acetylcholine receptors (nAChRs)
- breast cancer cells
- αO-conotoxin GeXIVA
- targeted therapy
- gorgonian
- Leptogorgia
- humulane sesquiterpenoids
- anticancer activity
- 12-deacetyl-12-epi-scalaradial
- HeLa cells
- Nur77
- MAPK/ERK pathway
- Mycalin A
- C15 acetogenins
- synthetic analogues
- antiproliferative activity
- A375 and HeLa cell lines
- polyoxygenated steroids
- sponge
- Haliclona gracilis
- Thalassia testudinum
- thalassiolin B
- polyphenols
- CYP1A1
- benzo[a]pyrene
- JNK1/2
- natural products
- synergism
- A549 cells
- cytoskeleton
- P2X7 receptor
- pollution
- anti-angiogenic
- gene expression
- HSP90
- inhibitor
| Item type | Home library | Collection | Call number | Materials specified | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|---|
Electronic-Books
|
OPJGU Sonepat- Campus | E-Books Open Access | Available |
Open Access star Unrestricted online access
The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U®), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.
Creative Commons https://creativecommons.org/licenses/by/4.0/ cc https://creativecommons.org/licenses/by/4.0/
English
There are no comments on this title.